Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

Published:2023-10 Issue:10 Volume:24 Page:1094-1108
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Saad Fred,Clarke Noel W,Oya Mototsugu,Shore Neal,Procopio Giuseppe,Guedes João Daniel,Arslan Cagatay,Mehra Niven,Parnis Francis,Brown Emma,Schlürmann Friederike,Joung Jae Young,Sugimoto Mikio,Sartor Oliver,Liu Yu-Zhen,Poehlein Christian,Barker Laura,del Rosario Paula Michelle,Armstrong Andrew J

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study;Ryan;Lancet Oncol,2015

2. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer from the PREVAIL trial;Armstrong;Eur Urol,2020

3. Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry;Francini;Prostate Cancer Prostatic Dis,2019

4. Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors;Shore;Adv Ther,2021

5. A hormone-DNA repair circuit governs the response to genotoxic insult;Goodwin;Cancer Discov,2013

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2024-12

2. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives;Clinical Genitourinary Cancer;2024-10

3. A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer;The Prostate;2024-09-09

4. Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing;ESMO Open;2024-09

5. PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers;European Urology Focus;2024-09